Skip to content

Nordicus Launches NoviThera to Revolutionize Psoriasis Treatment

NoviThera's innovative human rat model could transform psoriasis treatment. CEO Allan Wehnert leads the charge.

This image is clicked in a room, where it looks like Store. There are so many bottles in this image...
This image is clicked in a room, where it looks like Store. There are so many bottles in this image and cans. There is a Banner in the middle which is indicating Supra brand. Bottom right corner there is a logo LM.

Nordicus Launches NoviThera to Revolutionize Psoriasis Treatment

Nordicus Partners Corporation (OTCQB: NORD) has launched NoviThera Aps, a new venture dedicated to researching and developing a novel Monoclonal antibody (mAb) for psoriasis treatment. Allan Wehnert has been appointed as the CEO of NoviThera.

Psoriasis, an immune-mediated inflammatory disease, is typically treated with topical creams, phototherapy, and interleukin antibodies. NoviThera's key focus is to develop a human rat model that selectively expresses the endogenous pathological peptides and test it in relevant animal disease models. This innovative approach aims to create a more effective treatment for psoriasis patients.

The psoriasis treatment was originally invented by Alteral Therapeutics in Denmark and has been acquired by NoviThera for further development. NoviThera is developing a novel anti-mAb treatment that aims to cure or prevent psoriasis. The company's goal is to create a therapy that can significantly improve the lives of psoriasis patients.

Nordicus Partners Corporation, a U.S.-based business accelerator and holding company, specializes in corporate finance activities for Nordic life sciences companies. In 2024, Nordicus acquired 100% of Orocidin A/S and Bio-Convert A/S, both Danish preclinical-stage biotech companies, demonstrating its commitment to the Nordic biotech industry.

NoviThera Aps, under the leadership of CEO Allan Wehnert, is poised to make significant strides in psoriasis treatment. By developing a human rat model and testing it in relevant animal disease models, NoviThera aims to create a novel mAb therapy that could potentially cure or prevent psoriasis. Nordicus Partners Corporation, as the parent company, is dedicated to supporting and accelerating the growth of Nordic life sciences companies.

Read also:

Latest